author-photo

M. Yassine

Amgen

9

Papers

477

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer

2011 Clinical Colorectal Cancer
Show All
- Source
- Cite
- Save
Citations (31)
The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS Status

2011 Clinical Colorectal Cancer
Show All
- Source
- Cite
- Save
Citations (30)
6083 Final results from PRECEPT: efficacy and safety of second-line treatment with panitumumab and FOLFIRI in patients with metastatic colorectal cancer (mCRC)

2009 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (2)
Updated results of STEPP, a phase 2, open-label study of pre-emptive versus reactive skin toxicity treatment in metastatic colorectal cancer (MCRC) patients receiving panitumumab plus folfiri or irinotecan-only chemotherapy as second-line treatment

2008 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (13)
Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI

2008 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)